Next Article in Journal
‘Low-Salt’ Bread as an Important Component of a Pragmatic Reduced-Salt Diet for Lowering Blood Pressure in Adults with Elevated Blood Pressure
Next Article in Special Issue
Dietary and Supplement-Based Complementary and Alternative Medicine Use in Pediatric Autism Spectrum Disorder
Previous Article in Journal
Phenolic Composition of Artichoke Waste and Its Antioxidant Capacity on Differentiated Caco-2 Cells
Previous Article in Special Issue
Nutraceutical Potential of Carica papaya in Metabolic Syndrome
Review

Exploring the Science behind Bifidobacterium breve M-16V in Infant Health

1
Next Generation Science Institute, Morinaga Milk Industry Co., Ltd., Zama, Kanagawa 252-8583, Japan
2
Food Ingredients and Technology Institute, Morinaga Milk Industry Co., Ltd., Zama, Kanagawa 252-8583, Japan
*
Author to whom correspondence should be addressed.
Nutrients 2019, 11(8), 1724; https://doi.org/10.3390/nu11081724
Received: 9 July 2019 / Revised: 22 July 2019 / Accepted: 24 July 2019 / Published: 25 July 2019
(This article belongs to the Special Issue Nutraceutical, Nutrition Supplements and Human Health)
Probiotics intervention has been proposed as a feasible preventative approach against adverse health-related complications in infants. Nevertheless, the umbrella concept of probiotics has led to a massive application of probiotics in a range of products for promoting infant health, for which the strain-specificity, safety and efficacy findings associated with a specific probiotics strain are not clearly defined. Bifidobacterium breve M-16V is a commonly used probiotic strain in infants. M-16V has been demonstrated to offer potential in protecting infants from developing the devastating necrotising enterocolitis (NEC) and allergic diseases. This review comprehends the potential beneficial effects of M-16V on infant health particularly in the prevention and treatment of premature birth complications and immune-mediated disorders in infants. Mechanistic studies supporting the use of M-16V implicated that M-16V is capable of promoting early gut microbial colonisation and may be involved in the regulation of immune balance and inflammatory response to protect high-risk infants from NEC and allergies. Summarised information on M-16V has provided conceptual proof of the use of M-16V as a potential probiotics candidate aimed at promoting infant health, particularly in the vulnerable preterm population. View Full-Text
Keywords: Bifidobacterium breve M-16V; infant health; clinical efficacy; probiotics; gut microbiota Bifidobacterium breve M-16V; infant health; clinical efficacy; probiotics; gut microbiota
Show Figures

Graphical abstract

MDPI and ACS Style

Wong, C.B.; Iwabuchi, N.; Xiao, J.-z. Exploring the Science behind Bifidobacterium breve M-16V in Infant Health. Nutrients 2019, 11, 1724. https://doi.org/10.3390/nu11081724

AMA Style

Wong CB, Iwabuchi N, Xiao J-z. Exploring the Science behind Bifidobacterium breve M-16V in Infant Health. Nutrients. 2019; 11(8):1724. https://doi.org/10.3390/nu11081724

Chicago/Turabian Style

Wong, Chyn B., Noriyuki Iwabuchi, and Jin-zhong Xiao. 2019. "Exploring the Science behind Bifidobacterium breve M-16V in Infant Health" Nutrients 11, no. 8: 1724. https://doi.org/10.3390/nu11081724

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop